{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:23:14Z","timestamp":1787678594065,"version":"build-2784847793"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T00:00:00Z","timestamp":1716681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.biopha.2024.116820","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T20:07:16Z","timestamp":1716926836000},"page":"116820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Intraperitoneal pharmacokinetics of systemic oxaliplatin, 5-fluorouracil and bevacizumab in patients with colorectal peritoneal metastases"],"prefix":"10.1016","volume":"176","author":[{"given":"Pascale C.S.","family":"Rietveld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels A.D.","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.G.","family":"van Eerden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine L.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3372-5756","authenticated-orcid":false,"given":"Peter","family":"de Bruijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan D.T.","family":"Sassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva V.E.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit C.P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus W.A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn L.W.","family":"Koolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.116820_bib1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejca.2016.07.002","article-title":"Challenging the dogma of colorectal peritoneal metastases as an untreatable condition: results of a population-based study","volume":"65","author":"Razenberg","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2024.116820_bib2","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.ejso.2020.11.135","article-title":"Increase in the incidence of synchronous and metachronous peritoneal metastases in patients with colorectal cancer: a nationwide study","volume":"47","author":"Lurvink","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2024.116820_bib3","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.ejso.2021.12.004","article-title":"Treatment of metachronous colorectal cancer metastases in the Netherlands: a population-based study","volume":"48","author":"Meyer","year":"2022","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.biopha.2024.116820_bib4","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/309417","article-title":"Cytoreductive surgery plus hyperthermic perioperative chemotherapy for selected patients with peritoneal metastases from colorectal cancer: a new standard of care or an experimental approach?","volume":"2012","author":"Sugarbaker","year":"2012","journal-title":"Gastroenterol. Res. Pract."},{"issue":"20","key":"10.1016\/j.biopha.2024.116820_bib5","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116820_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2024.116820_bib7","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116820_bib8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1200\/JCO.2011.37.1039","article-title":"Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841","volume":"30","author":"Franko","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2024.116820_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.07.002","article-title":"A narrative review of what can HIPEC do","volume":"49","author":"Sugarbaker","year":"2023","journal-title":"Eur. J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116820_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4251\/wjgo.v2.i1.19","article-title":"Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer","volume":"2","author":"Sugarbaker","year":"2010","journal-title":"World J. Gastrointest. Oncol."},{"key":"10.1016\/j.biopha.2024.116820_bib11","unstructured":"Drugbank. Oxaliplatin 2005 [updated 05-01-2023. Available from: \u3008https:\/\/go.drugbank.com\/drugs\/DB00526\u3009."},{"key":"10.1016\/j.biopha.2024.116820_bib12","unstructured":"Drugbank. Fluorouracil 2005 [updated 05-01-2023. Available from: \u3008https:\/\/go.drugbank.com\/drugs\/DB00544\u3009."},{"issue":"5","key":"10.1016\/j.biopha.2024.116820_bib13","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1021\/acs.jpclett.2c03590","article-title":"Cellular uptake of bevacizumab in cervical and breast cancer cells revealed by single-molecule spectroscopy","volume":"14","author":"Karpinska","year":"2023","journal-title":"J. Phys. Chem. Lett."},{"issue":"11","key":"10.1016\/j.biopha.2024.116820_bib14","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1093\/bjs\/znad228","article-title":"Phase I study of intraperitoneal irinotecan combined with palliative systemic chemotherapy in patients with colorectal peritoneal metastases","volume":"110","author":"van Eerden","year":"2023","journal-title":"Br. J. Surg."},{"issue":"2","key":"10.1016\/j.biopha.2024.116820_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-022-01828-7","article-title":"Intraperitoneal chemotherapy for unresectable peritoneal surface malignancies","volume":"83","author":"Guchelaar","year":"2023","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.biopha.2024.116820_bib16","article-title":"Cross-validation of a multiplex LC-MS\/MS method for assaying mAbs plasma levels in patients with cancer: a GPCO-UNICANCER study","volume":"14","author":"Marin","year":"2021","journal-title":"Pharm. (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2024.116820_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1081\/CBI-120002597","article-title":"Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics","volume":"19","author":"Milano","year":"2002","journal-title":"Chronobiol. Int."},{"issue":"1","key":"10.1016\/j.biopha.2024.116820_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bcp.13773","article-title":"Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure","volume":"85","author":"de Jong","year":"2019","journal-title":"Br. J. Clin. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2024.116820_bib19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.critrevonc.2015.04.004","article-title":"Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer","volume":"95","author":"Braam","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116820_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1515\/pp-2017-0010","article-title":"Pharmacological principles of intraperitoneal and bidirectional chemotherapy","volume":"2","author":"de Bree","year":"2017","journal-title":"Pleura Peritoneum"},{"issue":"6","key":"10.1016\/j.biopha.2024.116820_bib21","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ejso.2006.03.004","article-title":"Heated intra-operative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: pharmacologic studies","volume":"32","author":"Elias","year":"2006","journal-title":"Eur. J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116820_bib22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1179\/joc.2011.23.1.28","article-title":"Pharmacokinetics of oxaliplatin in gastrointestinal cancer patients with malignant ascites","volume":"23","author":"Kochi","year":"2011","journal-title":"J. Chemother."},{"issue":"1","key":"10.1016\/j.biopha.2024.116820_bib23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00280-020-04107-y","article-title":"Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX study","volume":"86","author":"de Jong","year":"2020","journal-title":"Cancer Chemother. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2024.116820_bib24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdf019","article-title":"Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution","volume":"13","author":"Elias","year":"2002","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116820_bib25","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1038\/s41467-022-32198-z","article-title":"Molecular characterization of colorectal cancer related peritoneal metastatic disease","volume":"13","author":"Lenos","year":"2022","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.biopha.2024.116820_bib26","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/bjs.11206","article-title":"Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy","volume":"106","author":"Ubink","year":"2019","journal-title":"Br. J. Surg."},{"issue":"12","key":"10.1016\/j.biopha.2024.116820_bib27","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/s41416-022-01742-5","article-title":"Peritoneal metastases from colorectal cancer belong to consensus molecular subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity","volume":"126","author":"Laoukili","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.biopha.2024.116820_bib28","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/jamaoncol.2016.2314","article-title":"Clinical outcome from oxaliplatin treatment in stage II\/III colon cancer according to intrinsic subtypes: secondary analysis of NSABP C-07\/NRG oncology randomized clinical trial","volume":"2","author":"Song","year":"2016","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2024.116820_bib29","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/jso.21702","article-title":"Pharmacology of perioperative 5-fluorouracil","volume":"102","author":"Van der Speeten","year":"2010","journal-title":"J. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116820_bib30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/cpt.211","article-title":"Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: translating TNF-alpha experience to oncology","volume":"99","author":"Oude Munnink","year":"2016","journal-title":"Clin. Pharm. Ther."},{"issue":"19","key":"10.1016\/j.biopha.2024.116820_bib31","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1200\/JCO.2002.12.075","article-title":"Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer","volume":"20","author":"Falcone","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116820_bib32","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1200\/JCO.1999.17.6.1751","article-title":"Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics","volume":"17","author":"Wasserman","year":"1999","journal-title":"J. Clin. Oncol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224007042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224007042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:11:11Z","timestamp":1781651471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224007042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":32,"alternative-id":["S0753332224007042"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116820","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraperitoneal pharmacokinetics of systemic oxaliplatin, 5-fluorouracil and bevacizumab in patients with colorectal peritoneal metastases","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116820","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116820"}}